SCHEMBL771518

SCHEMBL771518

O=C(CCNC(=O)N1CCCC2CCCCC21)N1CCN(Cc2ccccc2)CC1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.52
DRD4 P21917 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
POLB P06746 1/20 0.49
ALDH1A1 P00352 3/20 0.48
LMNA P02545 1/20 0.47
HTT P42858 1/20 0.47
HTR7 P34969 2/20 0.47
KDM4E B2RXH2 2/20 0.46
MAPT P10636 1/20 0.46
HRH3 Q9Y5N1 1/20 0.46
FAAH O00519 1/20 0.46
EPHX2 P34913 2/20 0.44
DPP7 Q9UHL4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL770225 0.94 DRD2 (0.50) DRD2DRD4SMN1; SMN2NPC1RAB9A
SCHEMBL770315 0.85 DRD2 (0.58) DRD2DRD4SMN1; SMN2POLBALDH1A1
SCHEMBL770126 0.85 DRD2 (0.58) DRD2DRD4SMN1; SMN2POLBALDH1A1
SCHEMBL770096 0.81 NPC1 (0.55) SMN1; SMN2NPC1RAB9APOLBALDH1A1
SCHEMBL791314 0.81 POLB (0.52) DRD2DRD4SMN1; SMN2POLBALDH1A1
SCHEMBL770864 0.81 NPC1 (0.46) DRD2DRD4SMN1; SMN2NPC1RAB9A
SCHEMBL770244 0.81 NPC1 (0.46) DRD2DRD4SMN1; SMN2NPC1RAB9A
SCHEMBL771182 0.81 NPC1 (0.46) DRD2DRD4SMN1; SMN2NPC1RAB9A
SCHEMBL770612 0.81 HRH3 (0.57) SMN1; SMN2NPC1RAB9APOLBHRH3
SCHEMBL770070 0.80 AR (0.49) SMN1; SMN2NPC1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 DRD2 1422/4885DRD4 1484/4885SMN1; SMN2 3653/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 DRD2 1418/4885DRD4 1487/4885SMN1; SMN2 3637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.